Related Experiment Video
Updated: May 23, 2026
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
TLR ligand-peptide conjugate vaccines: toward clinical application
Gijs G P Zom1, Selina Khan, Dmitri V Filippov
1Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands.
Abstract:
Approaches to treat cancer with therapeutic vaccination have made significant progress. In order to induce efficient antitumor immunity, a vaccine should target and activate antigen-presenting cells, such as the dendritic cell, while delivering the tumor-derived antigen of choice. Conjugates of synthetic peptides and ligands of pattern-recognition receptors (PRRs) combine these features and, given their synthetic nature, can be produced under GMP conditions. Therefore, conjugation of antigenic peptides to potent PRR ligands is a promising vaccination approach for the treatment of cancer. This review focuses on the different PRR families that can be exploited for the design of conjugates and explores the results obtained so far with PRR ligands conjugated to antigen. The uptake and processing of Toll-like receptor ligand-peptide conjugates are discussed in more detail, as well as future directions that may further enhance the immunogenicity of conjugates.
Insights
Synthetic peptide-pattern recognition receptor (PRR) ligand conjugates offer a promising strategy for cancer treatment by activating antigen-presenting cells. This approach enhances antitumor immunity for effective cancer vaccination.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Therapeutic cancer vaccination has advanced significantly.
- Effective vaccines require targeting antigen-presenting cells (APCs) and delivering tumor antigens.
- Conjugates of synthetic peptides and pattern-recognition receptor (PRR) ligands offer a dual function for cancer treatment.
Purpose of the Study:
- To review PRR families for conjugate design in cancer vaccination.
- To explore existing results of PRR ligand-antigen conjugates.
- To discuss the mechanisms and future directions for enhancing conjugate immunogenicity.
Main Methods:
- Review of scientific literature on PRR ligands and peptide conjugates.
- Analysis of studies investigating the efficacy of PRR ligand-peptide conjugates in cancer therapy.
- Detailed examination of Toll-like receptor (TLR) ligand-peptide conjugate uptake and processing.
Main Results:
- Conjugates of synthetic peptides and PRR ligands can be produced under Good Manufacturing Practice (GMP) conditions.
- PRR ligands can be conjugated to tumor-derived antigens to enhance immune responses.
- TLR ligand-peptide conjugates show potential for targeted activation of APCs.
Conclusions:
- Conjugation of antigenic peptides to PRR ligands is a viable and promising vaccination strategy for cancer treatment.
- Further research into PRR families and conjugate design can optimize cancer immunotherapy.
- Enhancing the immunogenicity of these conjugates is key for future therapeutic success.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022